24P EGFR PACC mutations occur more frequently in compound than classical mutations with improved responses to TKIs

Mutations (single nucleotide variants), deletions, and insertions in the kinase domain of EGFR gene are oncogenic drivers in NSCLC. These alterations can co-occur with one another (compound mutations) or exist as single mutations. The compound vs single mutation frequencies for classical and EGFR P-loop and αC-helix compressing (PACC) mutations have not been characterized and the impact of compound mutations on treatment outcomes are not understood.